Industry
Biotechnology: modalities, manufacturing, tools and approval
Drug development is usually described as a science problem. Increasingly it is a manufacturing and regulatory one: several of the most demanded medicines of recent years were limited not by whether they worked but by how many doses could be filled, and by approvals that are specific to a process and a site.
The most useful first question about a medicine is what kind of thing it is. A small molecule is synthesised chemically, costs cents a dose and loses most of its price the day exclusivity ends. An antibody is grown in living cells, costs orders of magnitude more, and keeps much of its price because a competitor cannot copy it exactly. A cell therapy is manufactured one patient at a time. Those are not variations on a theme; they are different industries.
The manufacturing segment is the part of this branch that most resembles the rest of the map. It has capacity built years ahead of demand, consumables from single qualified suppliers, multi-year lead times on plant, and a qualification regime that makes substitution slow. When a recent injectable medicine was in shortage, the constraint was sterile filling and device assembly — an ordinary manufacturing capability, not the chemistry.
The tools segment sells to everyone regardless of whose drug succeeds, on an installed-base model: an instrument at modest margin and proprietary consumables for its life. It is also where semiconductor manufacturing shows up unexpectedly — sequencing flow cells are patterned with the same lithography used for chips, and that is what set the cost curve for reading a genome.
The last segment is the one that decides whether any of it reaches a patient. Trials are gated by recruitment rather than by science, approval covers the process and the site rather than only the molecule, and a product that survives all of it can still be ruined by a few hours at the wrong temperature.
How this breaks down
Split by what the medicine is, how it is made, what tools make it possible, and what lets it be sold.
- Biotechnologythis page
- Drug modalitiesSmall molecules, antibodies, mRNA, cell and gene therapy, peptides and oligonucleotides — and why the differences are structural.Breaks down into: Small molecules · Monoclonal antibodies · mRNA and lipid nanoparticles · Cell and gene therapy · Peptides and GLP-1 · Oligonucleotide therapeutics10 pages belowChokepoint
- BiomanufacturingBioreactors, single-use plastics, chromatography and sterile filling — the capacity that gates every biologic.Breaks down into: Media and reagents · Chromatography resins · Primary packaging · Viral vector manufacturing · Cell culture · Single-use systems · Purification · Fill-finish15 pages belowChokepoint
- Research toolsSequencing, gene editing and analytical instruments — the picks and shovels of the industry.Breaks down into: DNA sequencing · Gene editing · Analytical instruments3 pages belowChokepoint
- Clinical and regulatoryPhased trials, the approval standard, and the cold chain that carries the result.Breaks down into: Clinical trials · Regulatory approval · Cold chain6 pages belowChokepoint
What this depends on
4 of these are marked as a chokepoint: a handful of qualified suppliers, a multi-year lead time, or a single geography.
- Supply chainChokepoint
Sterile fill-finish and device capacity
The most frequently binding constraint in recent drug shortages, and one that takes years to add and qualify.
Fill-finish - Supply chainChokepoint
Single-use bioprocess consumables
Qualified per process and per product, which is why a shortage cannot be met by buying an equivalent elsewhere.
Single-use systems - StandardChokepoint
Regulatory approval of process and site
Capacity is not fungible: a product is approved as made a specific way in a specific place.
Regulatory approval - Supply chain
Semiconductor patterning for sequencing consumables
Sequencing flow cells are patterned with lithography from the chip industry, which is what drove the cost of reading a genome down.
Photolithography - TechnologyChokepoint
Clinical evidence
Nothing here reaches a patient without trials that demonstrate benefit, and how quickly those trials recruit sets most of a development timeline.
Clinical trials - Resource
Long-duration capital
A programme spends for a decade before any revenue, and the cost of the candidates that fail is carried by the few that succeed.
Companies across Biotechnology
Every company named on a step below this page, ordered by how many of those steps it appears at. Compiled from the pages themselves rather than written separately, so the two cannot disagree. Not a ranking and not a recommendation.
mRNA synthesis · Lipid nanoparticles · Cell and gene therapy · In vivo gene therapy · Cell culture media · Nucleic acid reagents · Process chemicals and excipients · Viral vector manufacturing · Cell culture · Single-use systems · Purification · Fill-finish · DNA sequencing · Gene editing · Analytical instruments · Clinical trials · Cold chain packaging
- Merck KGaAGermany9 steps
Lipid nanoparticles · Cell culture media · Nucleic acid reagents · Specialty lipids · Process chemicals and excipients · Chromatography resins · Cell culture · Single-use systems · Purification
- Lonza GroupSwitzerland8 steps
Small molecules · Monoclonal antibodies · mRNA synthesis · Lipid nanoparticles · Cell and gene therapy · Engineered cell therapy · In vivo gene therapy · Cell culture media
- SartoriusGermany5 steps
Cell culture media · Chromatography resins · Cell culture · Single-use systems · Purification
- Roche HoldingSwitzerland4 steps
Monoclonal antibodies · In vivo gene therapy · Oligonucleotide therapeutics · Regulatory approval
122 more companies appear at a single step each; they are named on the pages for those steps.
How these pages are written
Each page explains one technology in plain language, states what it depends on, and names companies by what they supply at that step. Company roles are described qualitatively and deliberately carry no market shares, revenue figures or rankings — those change faster than an explainer can, and a stale number is worse than none. Ticker links point at company pages on this site and are provided for reference only.
Nothing here is investment advice, a recommendation, or a forecast. A company named on a page about a technology is not thereby a good investment, and the chokepoints described are structural facts about supply chains rather than predictions about prices. Technology moves; where a page describes something as unresolved or in development, that was true when it was written.
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer